Katherine Alpaugh

1.2k total citations
18 papers, 519 citations indexed

About

Katherine Alpaugh is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Katherine Alpaugh has authored 18 papers receiving a total of 519 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Cancer Research and 6 papers in Molecular Biology. Recurrent topics in Katherine Alpaugh's work include Cancer Cells and Metastasis (5 papers), Immunotherapy and Immune Responses (5 papers) and Cancer Genomics and Diagnostics (4 papers). Katherine Alpaugh is often cited by papers focused on Cancer Cells and Metastasis (5 papers), Immunotherapy and Immune Responses (5 papers) and Cancer Genomics and Diagnostics (4 papers). Katherine Alpaugh collaborates with scholars based in United States, Belgium and France. Katherine Alpaugh's co-authors include Antonio C. Wolff, Anne O’Neill, Chau T. Dang, Kathy D. Miller, Donald W. Northfelt, George W. Sledge, Joseph A. Sparano, Massimo Cristofanilli, Sandra V. Fernandez and Neal J. Meropol and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Katherine Alpaugh

18 papers receiving 510 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Katherine Alpaugh United States 10 318 297 166 117 72 18 519
Marco Petronio France 4 407 1.3× 313 1.1× 166 1.0× 113 1.0× 41 0.6× 5 567
Anne Renolen Norway 9 385 1.2× 252 0.8× 110 0.7× 98 0.8× 49 0.7× 13 468
Coyin Oh United States 5 316 1.0× 211 0.7× 208 1.3× 111 0.9× 143 2.0× 8 636
Dorota Kwapisz Poland 6 346 1.1× 256 0.9× 205 1.2× 302 2.6× 45 0.6× 9 608
Devang Panchal Canada 5 303 1.0× 190 0.6× 235 1.4× 108 0.9× 33 0.5× 7 511
Amber Anderson United States 8 515 1.6× 385 1.3× 147 0.9× 166 1.4× 40 0.6× 8 618
Kumari L. Andarawewa United States 10 272 0.9× 248 0.8× 255 1.5× 60 0.5× 19 0.3× 12 561
Leyre Larzábal Spain 11 251 0.8× 177 0.6× 299 1.8× 68 0.6× 29 0.4× 14 519
Meleah Cameron United States 3 244 0.8× 130 0.4× 141 0.8× 64 0.5× 52 0.7× 6 386
Ramya Kumareswaran Canada 8 187 0.6× 214 0.7× 271 1.6× 105 0.9× 37 0.5× 9 445

Countries citing papers authored by Katherine Alpaugh

Since Specialization
Citations

This map shows the geographic impact of Katherine Alpaugh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine Alpaugh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine Alpaugh more than expected).

Fields of papers citing papers by Katherine Alpaugh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine Alpaugh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine Alpaugh. The network helps show where Katherine Alpaugh may publish in the future.

Co-authorship network of co-authors of Katherine Alpaugh

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine Alpaugh. A scholar is included among the top collaborators of Katherine Alpaugh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine Alpaugh. Katherine Alpaugh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Singh, Tanu, et al.. (2024). TIP24-198: A Multi-Center Phase I Trial of Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Refractory Gastric Cancer Patients. Journal of the National Comprehensive Cancer Network. 22(2.5). 1 indexed citations
2.
Whitaker, Kristen, Eric A. Ross, James E. Klaunig, et al.. (2022). Assessing association of heavy metal levels in urine and sera with neurotoxicity in breast cancer(BC) patients undergoing adjuvant/neoadjuvant chemotherapy.. Journal of Clinical Oncology. 40(16_suppl). e12510–e12510. 1 indexed citations
3.
Gong, Yulan, Maria F. Arisi, Lorenzo Gerratana, et al.. (2021). Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC). International Journal of Molecular Sciences. 22(16). 8924–8924. 1 indexed citations
4.
Bilušić, Marijo, Daniel M. Girardi, Yan Zhou, et al.. (2020). Molecular Profiling of Exceptional Responders to Cancer Therapy. The Oncologist. 26(3). 186–195. 14 indexed citations
5.
Cohen, Adam D., Nikoletta Lendvai, Sarah Nataraj, et al.. (2019). Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine–Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma. Cancer Immunology Research. 7(4). 658–669. 14 indexed citations
6.
Sparano, Joseph A., Anne O’Neill, Katherine Alpaugh, et al.. (2018). Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor–Positive Breast Cancer. JAMA Oncology. 4(12). 1700–1700. 149 indexed citations
7.
O’Neill, Anne, et al.. (2018). Abstract GS6-03: Circulating tumor cells (CTCs) five years after diagnosis are prognostic for late recurrence in operable stage II-III breast cancer. Cancer Research. 78(4_Supplement). GS6–3. 13 indexed citations
8.
9.
Fernandez, Sandra V., Catherine A. Bingham, Laura Austin, et al.. (2014). TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients. Breast Cancer Research. 16(5). 445–445. 86 indexed citations
10.
11.
12.
Robertson, Fredika M., Emanuel F. Petricoin, Steven Van Laere, et al.. (2013). Presence of anaplastic lymphoma kinase in inflammatory breast cancer. SpringerPlus. 2(1). 497–497. 40 indexed citations
13.
Mu, Zhaomei, Hua Li, Sandra V. Fernandez, et al.. (2013). EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells. Journal of Experimental & Clinical Cancer Research. 32(1). 34 indexed citations
14.
Doss, Mohan, Jinjun Zhang, James B. Stubbs, et al.. (2010). Biodistribution and radiation dosimetry of the hypoxia marker 18F–HX4 in monkeys and humans determined by using whole-body PET/CT. Nuclear Medicine Communications. 31(12). 1016–1024. 43 indexed citations
15.
Dotan, Efrat, Steven J. Cohen, Katherine Alpaugh, & Neal J. Meropol. (2009). Circulating Tumor Cells: Evolving Evidence and Future Challenges. The Oncologist. 14(11). 1070–1082. 60 indexed citations
16.
Borghaei, Hossein, Katherine Alpaugh, Gunnar Hedlund, et al.. (2009). Phase I Dose Escalation, Pharmacokinetic and Pharmacodynamic Study of Naptumomab Estafenatox Alone in Patients With Advanced Cancer and With Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 27(25). 4116–4123. 44 indexed citations
17.
Alpaugh, Katherine & Margaret von Mehren. (1999). Monoclonal Antibodies in Cancer Treatment. BioDrugs. 12(3). 209–236. 6 indexed citations
18.
Alpaugh, Katherine, et al.. (1985). A Donor Population Classified For Viral Exposure and Infection: Cytomegalovirus and Hepatitis B, With an Addendum on HTLV-III Test Results. Laboratory Medicine. 16(8). 485–488. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marco Petronio Breakdown of academic impact, for papers by Anne Renolen Breakdown of academic impact, for papers by Coyin Oh Breakdown of academic impact, for papers by Dorota Kwapisz Breakdown of academic impact, for papers by Devang Panchal Breakdown of academic impact, for papers by Amber Anderson Breakdown of academic impact, for papers by Kumari L. Andarawewa Breakdown of academic impact, for papers by Leyre Larzábal Breakdown of academic impact, for papers by Meleah Cameron Breakdown of academic impact, for papers by Ramya Kumareswaran
Rankless by CCL
2026